Several clinical trials have examined anti-PD-1/anti-PD-L1 antibody therapy combined with the cabozantinib/regorafenib regimens to boost ORR and OS in advanced cancers, such as RCC, hepatocellular carcinoma (HCC), and metastatic colorectal cancer (mCC). Here, PDCD1 is linked to Merkel cell skin cancer.